The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.
 
Antonio Calles
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Sanofi/Regeneron; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; IGEN BIOTECH; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Sanofi/Regeneron; Takeda
Research Funding - MSD Oncology
 
Alejandro Navarro
Consulting or Advisory Role - Boehringer Ingelheim; Bristol Myers Squibb Foundation; Pfizer
Speakers' Bureau - AstraZeneca Spain; Roche
Expert Testimony - Medsir; Oryzon Genomics
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Bernard Doger
No Relationships to Disclose
 
Maria J. de Miguel
Honoraria - Janssen; MSD; Roche
Consulting or Advisory Role - Syneos Health
Research Funding - Abbvie (Inst); Array BioPharma (Inst)
 
Rosa Maria Alvarez Alvarez
Honoraria - Bristol-Myers Squibb; PharmaMar; Roche/Genentech
Consulting or Advisory Role - GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche/Genentech
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); CEBIOTEX (Inst); Janssen Oncology; MSD Oncology (Inst); Novartis; PharmaMar (Inst); Rain Therapeutics; Roche/Genentech; Takeda (Inst)
Travel, Accommodations, Expenses - PharmaMar; Roche
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Basilea; Bayer; BMS; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Jorge Ramón
No Relationships to Disclose
 
María del Mar Galera López
Honoraria - MSD Oncology
Speakers' Bureau - MSD Oncology
Travel, Accommodations, Expenses - Lilly; MSD Oncology; Novartis; PharmaMar; Roche
 
Tatiana Hernandez-Guerrero
No Relationships to Disclose
 
Elena Corral
No Relationships to Disclose
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Alkermes; Amcure; Amunix; Anaveon; AstraZeneca/MedImmune; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Janssen-Cilag; MedSIR; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; PsiOxus Therapeutics; Roche/Genentech; Sanofi; Seagen; Servier; Syneos Health; T-Knife; TargImmune Therapeutics
Research Funding - Achilles Therapeutics (Inst); BeiGene; START
Other Relationship - Investigational Therapeutics in Oncological Sciences